ABSTRACT: Differentially expressed genes after miRNA or siRNA transfection in human cancer cell lines (A-498, 786-O, A549, TE-8, PANC-1, SW1990, PC3 and PC3M)
Project description:Screening of differentially expressed mRNAs in SW1990 and PANC-1 cells following GLI1 cDNA transfection. We independently transfected SW1990 and Panc-1 cells with Gli1 cDNA for mRNA and miRNA microarray analysis. The results unveiled significant differential expression patterns, with numerous miRNAs and mRNAs showing changes post-Gli1 transfection. Remarkably, miR-301a exhibited high expression in both SW1990 and Panc-1 cells transfected with Gli1 cDNA
Project description:Screening of differentially expressed miRNAs in SW1990 and PANC-1 cells following GLI1 cDNA transfection. We independently transfected SW1990 and Panc-1 cells with Gli1 cDNA for mRNA and miRNA microarray analysis. The results unveiled significant differential expression patterns, with numerous miRNAs and mRNAs showing changes post-Gli1 transfection. Remarkably, miR-301a exhibited high expression in both SW1990 and Panc-1 cells transfected with Gli1 cDNA.
Project description:Gene expression profiling of pancreatic cancer cell PANC-1 and SW1990 when LINC00842 knockdown by CRISPR/Cas9 system. We identified LINC00842 is a novel prognosis related lincRNA in pancreatic cancer and its regulation networks is poorly understood. We used the total RNA from knockdown control and LINC00842-knockdown PANC-1 and SW1990 cells to analyze the differentially expressed genes which were regulated by LINC00842, and further explored the biological processes that LINC00842 may involved.
Project description:Microarray analyses using CD166+ and CD166- pancreatic cancer cell lines from both Panc-1 and SW1990 cells. We carried out microarray analyses using the CD166+ and CD166- separated cells from both Panc-1 and SW1990. The quality of the RNA samples was evaluated using a 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). We used a Human HT-12v4 Expression BeadChip (Illumina, San Diego, CA) for these analyses. The data were analyzed using BeadStudio software version 3.2.3 (Illumina).
Project description:To identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines (bladder cancer, prostate cancer, renal cell carcinoma, oral squamous cell carcinoma and lung squamous cell carcinoma) were subjected to Agilent whole genome microarrays. Human cancer cell lines (SAS, HSC3, BOY, T24, PC3, PC3M, DU145, C4-2, 786-O, A-498 and EBC-1) were treated with miRNAs (miR-205, miR-29a, miR-144-3p, miR-144-5p, miR-451, miR-210, miR-145-5p, miR-145-3p, miR-23b cluster, miR-221, miR-222 and miR-223), siRNAs (si-GOLM1, si-HMGB3, si-CENPF, si-LOXL2, si-TMEM184B and si-CORO1C).
Project description:The objective of this study was to evaluate the consequences of Ago1 knockdown in metastatic prostate cancer cells PC3. To this end we profiled RNA from PC3 cells 72 hours following the transfection with a scramble siRNA (siGL3) and a siRNA targeting Ago1 (siAgo1).
